News

Cardinal Health has renewed its distribution agreement with CVS Caremark, to supply pharmaceuticals to its national network of retail pharmacies through mid 2013. George Barrett, Vice Chairman of

MorphoSys has announced that Novartis has committed to a ten-year term of the strategic alliance, originally signed in December 2007. The decision was based on the successful achievement

Three new small-and-medium-sized enterprises (SMEs) – Syncom, Synvolux and InteRNA, have signed a partnership agreement with TI Pharma by participating in two new projects. These projects would focus

Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx’s BL-1040. Its a potential treatment for preventing pathological cardiac remodeling, following acute myocardial infarction

Coapt Systems has launched Hydrelle, a new FDA-approved hyaluronic acid-based dermal filler, for the treatment of facial wrinkles. Hydrelle has been formulated with an anesthetic (lidocaine) for greater

Shire, at the request of the FDA, has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development, for the treatment of Gaucher Disease. Velaglucerase

Sanofi-aventis has published the results of the five-year study of Lantus (insulin glargine injection) versus NPH insulin, on progression of retinopathy in patients with type 2 diabetes. The

French pharmaceutical company Sanofi-aventis has unveiled the results of the five-year study of Lantus (insulin glargine injection) versus NPH insulin, on progression of retinopathy in patients with type

Oxford BioMedica has received final comments following the FDA’s review of the phase-III TRIST study of TroVax in renal cancer, and the proposed clinical development outline. FDA acknowledged